![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 2, 1398-1404, January 11, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, July 13, 2001, and in revised form, October 22, 2001
Leukotriene A4
hydrolase/aminopeptidase is a bifunctional zinc metalloenzyme that
converts the fatty acid epoxide leukotriene A4 into
leukotriene B4, a potent chemoattractant and
immune-modulating lipid mediator. Recently, the structure of
leukotriene A4 hydrolase revealed that Glu-271, which
belongs to a conserved GXMEN motif in the M1
family of zinc peptidases, and Gln-136 are located at the active site.
Here we report that mutagenetic replacements of Glu-271, but not
Gln-136, abrogate both catalytic activities of leukotriene
A4 hydrolase. Furthermore, the 2.1 Å crystal structure of
[E271Q]leukotriene A4 hydrolase revealed minimal
conformational changes that could not explain the loss of enzyme
function. We propose that the carboxylate of Glu-271 participates in an
acid-induced opening of the epoxide moiety of leukotriene
A4 and formation of a carbocation intermediate. Moreover,
Glu-271 appears to act as an N-terminal recognition site and may
potentially stabilize the transition-state during turnover of peptides,
a property that most likely pertains to all members of the M1 family of
zinc aminopeptidases. Hence, Glu-271 is a unique example of an amino
acid, which has dual and separate functions in two different catalytic
reactions, involving lipid and peptide substrates, respectively.
The leukotrienes (LTs)1
are potent chemical mediators in a variety of allergic and inflammatory
reactions (1, 2). In the biosynthesis of LTs, 5-lipoxygenase converts
arachidonic acid into the unstable epoxide LTA4. This
intermediate may in turn be conjugated with GSH to form the spasmogenic
LTC4 or hydrolyzed into the proinflammatory lipid mediator
LTB4, in a reaction catalyzed by LTA4 hydrolase
(LTA4H). The enzyme product LTB4 is a classical chemoattractant and triggers adherence and aggregation of leukocytes to
the endothelium at nanomolar concentrations (3). In addition, LTB4 modulates immune responses (4), participates in the
host-defense against infections (5, 6), and is a key mediator of
PAF-induced lethal shock (7, 8). These effects are signaled via
a specific, high-affinity, G protein-coupled receptor for
LTB4 (BLT1) (9). In addition, a
second receptor for LTB4 (BLT2) was
recently discovered, the functional role of which is presently not
known (10).
LTA4 hydrolase (EC 3.3.2.6) is a bifunctional zinc
metalloenzyme, which integrates a sophisticated epoxide hydrolase
activity, specific for the fatty acid derivative LTA4 with
an anion-dependent aminopeptidase activity in a common
active center; for a review see Ref.11. The enzyme belongs to the M1
family of zinc metallopeptidases (12), which include enzymes such as
aminopeptidase A (EC 3.4.11.7, APA), aminopeptidase B (EC 3.4.11.6,
APB) and aminopeptidase N (EC 3.4.11.2, APN) (see Fig. 1). A common
structural feature in this group of enzymes is the zinc binding motif
HEXXH(X18)E (13), and in LTA4H the
zinc is coordinated by His-295, His-299, and Glu-318 (14). Both enzyme
activities of LTA4H require the catalytic zinc.
The aminopeptidase activity accepts a variety of substrates and certain
arginyl di- and tripeptides as well as p-nitroanilide derivatives of Ala and Arg are hydrolyzed with high efficiencies (15).
Although it has never been proven, it is generally assumed that the
aminopeptidase activity is involved in the processing of peptides
related to inflammation and host-defense. Furthermore, this enzyme
activity can be selectively abolished by mutation of either of the
conserved Glu-296 or Tyr-383, presumably acting as a general base and
proton donor, respectively (16, 17). The members of the M1 family of
metallopeptidases also share a conserved motif,
GXMEN (Fig. 1), that is
located N-terminally to the zinc site, and for APA and APN recent data
have suggested that it participates in the exopeptidase function of
these enzymes (18, 19).
The epoxide hydrolase reaction, i.e. the conversion of
LTA4 into LTB4, is unique in that the
stereospecific introduction of a hydroxyl group occurs at a site
distant from the epoxide moiety, and it has been suggested that it
proceeds via a delocalized carbocation intermediate. Unlike the
aminopeptidase activity, the epoxide hydrolase activity of LTA4H is
restrained by suicide inactivation, which involves binding of
LTA4 to Tyr-378 (20, 21). However, besides the zinc binding
ligands, no single amino acid residue critical for the epoxide
hydrolase activity has yet been identified.
Recently, we determined the x-ray crystal structure of LTA4H at
1.95 Å resolution in complex with bestatin (22). In the structure,
Glu-271, which is located within the GXMEN motif, and Gln-136 are positioned at the active site near the catalytic residue Glu-296, as well as the catalytic zinc and its three amino acid ligands
(Fig. 2). Furthermore, Glu-271 and
Gln-136 make interactions with bestatin suggesting that they might be
involved in the aminopeptidase activity of LTA4H.
Leukotriene A4
Hydrolase/Aminopeptidase
GLUTAMATE 271 IS A CATALYTIC RESIDUE WITH SPECIFIC ROLES IN TWO
DISTINCT ENZYME MECHANISMS*
,
,
¶
Department of Medical Biochemistry and
Biophysics, Division of Chemistry II, Karolinska Institutet, S-171
77 Stockholm, Sweden and the § Department of Biochemistry,
University of Stockholm, Arrhenius Laboratories A4, S-106 91 Stockholm,
Sweden
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (19K):
[in a new window]
Fig. 1.
Conserved sequence motifs within the M1
family of metallopeptidases. The three zinc-binding ligands are
denoted L1, L2, and
L3. Catalytic residues are indicated for the
epoxide hydrolase activity (
) and/or the aminopeptidase activity
(
), respectively. Numbering of residues refers to the sequence of
LTA4H.

View larger version (44K):
[in a new window]
Fig. 2.
Structure of LTA4H, spatial
relationships between residues at the catalytic zinc site. The
figure depicts the juxtaposition of Glu-271 and Gln-136 relative the
known catalytic residues Glu-296 and Tyr-383 as well as the prosthetic
zinc. The inhibitor bestatin is depicted in light gray.
Hydrogen bonds are indicated with green dotted lines, and
the metal coordination with black dotted lines.
In the present report, we show that Glu-271, but not Gln-136, is a catalytic residue that is shared between the epoxide hydrolase and aminopeptidase activities of LTA4H. Yet, Glu-271 carries out a separate chemistry in each of the two reaction mechanisms. We propose mechanistic models in which Glu-271 both participates in the initial activation of the epoxide moiety of the substrate LTA4 and contributes to the binding of the N-terminal amine and the exopeptidase nature of the peptide-cleaving activity. Moreover, it is likely that the conclusions regarding the aminopeptidase activity are valid for all members of the M1 family of metallopeptidases and that the GXMEN sequence qualifies as a consensus motif for an N-terminal recognition site.
|
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Mutagenesis of Human LTA4H cDNA-- Site-directed mutagenesis was carried out by PCR on the recombinant plasmid pT3MB4 for expression of His6-tagged LTA4H in Escherichia coli. Briefly, it involves two consecutive steps of PCR comprising four different primers, according to the megaprimer method (23). The first reaction includes a modified primer (A) carrying the mutation and a second primer (B) comprising a restriction site within the LTA4H cDNA. Together, primers A and B amplify a DNA fragment denominated megaprimer. In the next PCR, the megaprimer is used together with a fourth primer (C) containing another restriction site to amplify a final fragment carrying the mutation and two different restriction sites at its ends. Polymerase chain reactions were carried out in a total volume of 50 µl, using 1× Pfu polymerase buffer, 125-150 ng each of primers A and B, 1 unit Pfu polymerase, 10 nmol each of dNTPs and 100 ng of template. In the second reaction, 15-20 µl of the first PCR mix was used to supply with the megaprimer, which was used together with a primer C (125-150 ng). The amplification program included an initial round of denaturation at 94 °C (60 s), annealing at 55-66 °C (60 s), and elongation at 72 °C (90 s) followed by 30 cycles of denaturation (45 s), annealing (30 s), and elongation (60 s) on a PE GeneAmp PCR System 2400.
For generation of [Q136L], [Q136N] and [Q136A]LTA4H, a
SalI and BglII site were used whereas a
BglII and a BfrI site were used for [G268A],
[G269A], [M270L], [E271Q], [E271D], [E271A] and
[N272A]LTA4H. DNA fragments were cleaved with
SalI/BglII or BglII/BfrI
and purified by agarose gel electrophoresis (1.5%) followed by
extraction (QIAEX II Gel Extraction Kit). Mutated fragments were
ligated into pT3MB4 (T4 DNA Ligase Protocol), opened with the
respective pair of restriction enzymes. Competent E. coli
cells (JM101) were transformed with mutated recombinant plasmid and
grown in LB medium containing ampicillin (100 µg/ml). Stock cultures
were kept at
70 °C in a 1:1 mixture of culture medium and 40%
(v/v) glycerol/0.75% (w/v) NaCl, respectively. Recombinant plasmids
were purified using Wizard Minipreps Plus, and the entire mutated
inserts were all sequenced using Dyenamic ET terminator cycle
sequencing kit (Amersham Biosciences, Inc.) to confirm that no
nucleotide alterations had occurred in addition to the desired mutation.
|
Protein Expression and Purification--
Mutated enzymes were
expressed as N-terminal His6-tagged fusion proteins
in E. coli (JM101) cells grown at 37 °C in M9 medium (50 mM Na2HPO4, 22 mM
KH2PO4, 20 mM NH4Cl,
8.5 mM NaCl), pH 7.4, containing 0.4% glucose (w/v), 0.2%
(w/v) casamino acids, 2 mM MgSO4 and 0.1 mM CaCl2. At A620
0.2, isopropyl-
-D-thiogalactopyranoside was added to
a final concentration of 500 µM. Cells were harvested at
A620
1.8, pelleted at 1000 × g and resuspended in 30 ml of homogenization buffer (50 mM Tris-HCl, pH 8.0, containing soybean trypsin inhibitor)
supplemented with phenylmethylsulfonyl fluoride (1 mM).
Nucleic acids were removed by streptomycin sulfate precipitation. After
centrifugation (10,000 × g for 15 min), the
supernatant was filtered (0.22 µm) and applied to a nickel-NTA
(nitrilotriacetic acid) resin. The column was washed with 1 bed volume
of 50 mM Tris-HCl, pH 8.0, 50 mM sodium
phosphate buffer, pH 6.8, and 0.5 M NaCl, and 50 mM Tris-HCl, pH 8.0, with each solution supplemented with
10 mM imidazole. The final wash consisted of 0.8 bed
volumes of 50 mM Tris-HCl, pH 8.0, containing 100 mM imidazole. The His-tagged protein was eluted with 0.6 bed volumes of 50 mM Tris-HCl, pH 8.0, containing 100 mM imidazole. If required, a final step of anion-exchange
chromatography on a Mono Q HR5/5 column was used. The resin was
equilibrated with 10 mM Tris-HCl, pH 8.0, and eluted with a
linear gradient of KCl (0-0.5 M) in 10 mM
Tris-HCl, pH 8.0. The purity of the final preparation was assessed by
SDS-PAGE on an Amersham Biosciences, Inc. Phast system using 10-15%
gradient gels, subsequently stained with Coomassie Brilliant Blue.
Protein concentrations were determined by the Bradford method using a MCC/340 96-well multiscan spectrophotometer and bovine serum albumin as
standard (24).
Aminopeptidase Activity Assays-- The aminopeptidase activity was determined in a spectrophotometric assay at 405 nm, using a MCC/340 multiscan spectrophotometer, essentially as described (25). Briefly, the enzyme (1-20 µg) was incubated at room temperature in 96-well microtiter plates with alanine-p-nitroanilide (Ala-p-NA) as substrate in 50 mM Tris-HCl, pH 8.0, containing 100 mM KCl. Additional aminopeptidase assays were performed similarly with Leu-p-NA and Lys-p-NA as substrates. The absorbance at 405 nm was measured at 10-min intervals. Different concentrations of substrate (0.125, 0.25, 0.5, 1, 2, 4, 8 mM) were used for kinetic determinations. Spontaneous hydrolysis of the substrate was corrected for by subtracting the absorbance of blank incubations without enzyme.
Epoxide Hydrolase Activity Assays and Reverse-phase
HPLC--
The epoxide hydrolase activity was determined from
incubations of enzyme (1-20 µg) in 100 µl of 10 mM
Tris-HCl, pH 8.0, with LTA4 (2.5-125 µM) for
30 s on ice. Reactions were quenched with 200 µl of MeOH,
followed by the addition of 0.4 nmol of prostaglandin B1
(PGB1) or PGB2 as internal standard. Samples
were acidified with 5 µl of acetic acid (10%), and metabolites were
extracted on solid phase Chromabond C18 columns. Enzymatic metabolites
of LTA4 were identified and quantified by reverse-phase
HPLC. Metabolites of LTA4 were separated by isocratic
reverse-phase HPLC on a Waters Nova-Pak C18 column eluted with a
mixture of methanol/acetonitrile/water/acetic acid (30:30:40:0.01 by
volume) at a flow rate of 1.2 ml/min. The UV detector was set at 270 nm, and metabolites were quantified using Chromatography Station for
Windows version 1.7 computer software. Calculations were based on peak
area measurements and the known extinction coefficients for the
internal standards PGB1 and PGB2 (30 000 M
1 × cm
1) as well as
LTB4 (50 000 M
1 × cm
1).
Crystallization-- Plate-like crystals of [E271Q]LTA4H were obtained by liquid-liquid diffusion in capillaries, as described (22). Briefly, 5 µl of precipitation solution (28% (v/v) PEG8000, 0.1 mM sodium acetate, 0.1 mM imidazole buffer, pH 6.8, and 5 mM YbCl3) was injected into the bottom of a melting point capillary, and an equal volume of LTA4H (5 mg/ml) in 10 mM Tris-HCl, pH 8, was layered on top.
Data Collection and Structure Determination--
For data
collection, crystals were soaked in 15% PEG8000, 50 mM
imidazole buffer, pH 6.8, 50 mM sodium-acetate, 2.5 mM YbCl3, and 25% glycerol and analyzed at the
Beamline I711 of the synchrotron station Max-Lab in Lund, Sweden. A
complete set of data was collected from a single crystal. The crystals
belonged to space-group P212121 with cell dimensions a = 77.962, b = 86.873, c = 98.787,
=
=
= 90° at 100 K. Statistics on data collection and quality are given in
Table I. Processing, scaling, and merging of data were carried out
using the program package Denzo/Scalepack (26). The structure of
[E271Q]LTA4H was solved with molecular replacement using the program
AMoRe (27), and the structure of wild type LTA4H as a search model
(22). All subsequent refinement was done using the CNS package (28) and
manual model building as well as interpretation of electron density
maps with the programs QUANTA (Molecular Simulations, Inc) and XtalView
(29). During the refinement 582 water molecules, one Zn2+
ion, one acetate molecule, and one Yb3+ ion were
identified. After a final round of refinement, including all data
between 25-2.1 Å and all 610 amino acids, the R-factor was
18.2% and the Rfree factor was 23.3%. Most of
the model of [E271Q]LTA4H is in good density except for the
His6 tag and the first four N-terminal residues.
The model exhibits a highly restrained but acceptable stereochemistry
with 99.6% of the residues lying in the most favored or additionally
allowed regions of the Ramachandran plot. Root mean square deviations
for bond lengths and angles are 0.01 Å and 1.6°, respectively.
Molecular Modeling--
To model the binding of
Ala-p-NA, the program AutoDock 3.0 (30) was used. The
substrate, assumed to be protonated with a positively charged amino
group, was initially modeled manually into the active site of LTA4H
using the program XtalView. The binding conformation was then optimized
using the local search algorithm of AutoDock 3.0. Prior to the docking,
addition of polar hydrogens and assignment of atomic charges to the
model of LTA4H was done using the program QUANTA, which was also used
to construct the atomic coordinates of Ala-p-NA. The program
MOPAC (31) was used to assign atomic partial charges to the ligand and
to further optimize its coordinates prior to the docking calculation.
In all other aspects of the docking process, programs included in the
AutoDock 3.0 program package were used.
| |
RESULTS |
|---|
|
|
|---|
Mutagenetic Replacements, Expression, and Purification of Recombinant Proteins-- To detail their function we exchanged Glu-271 for a Gln, Asp, or Ala residue, whereas Gln-136 was replaced with an Asn, Leu, and Ala by site-directed mutagenesis. In addition, the remaining residues in the GXMEN signature, viz. Gly-268, Gly-269, Met-270, and Asn-272 were mutated into Ala, Ala, Leu, and Ala, respectively. The resulting 10 mutants were all expressed as His6-tagged fusion proteins in E. coli to allow rapid and convenient purification on nickel-NTA resins. The level of expression was similar for wild type enzyme and all mutants, with a final yield of about 2-5 mg of purified protein per liter of cell culture.
Effects of Mutation of Glu-271-- Exchange of Glu-271 for a Gln, Asp, or Ala residue resulted in a complete loss of the epoxide hydrolase activity (Table II), even when the amounts of enzyme were increased 40 times (100 µg) in the incubation mixture. In contrast, mutants at the other positions within the GXMEN motif, i.e. [G268A], [G269A], [M270L], and [N272A]LTA4H, displayed variable, albeit significant, epoxide hydrolase activities. Thus, values of Vmax and kcat ranged between 19-135% relative to the wild type enzyme, whereas the corresponding values for Km ranged between 21-202%. As a result, the specificity constant kcat/Km varied between 67 and 117%.
The aminopeptidase activity of [E271Q], [E271D], and [E271A]LTA4H against Ala-p-NA was essentially abolished (Table II) and similar results were obtained with Lys-p-NA and Leu-p-NA (data not shown). In contrast, the aminopeptidase activity of [G268A], [G269A], [M270L], and [N272A]LTA4H were moderately, if at all, affected with values of Vmax (kcat) and Km ranging between 18-218% and 66-221%, respectively, relative to the wild type enzyme. The corresponding specificity constants were between 8 and 301% that of the wild type enzyme.
Effects of Mutation of Gln-136-- Exchange of Gln-136 for a Leu, Asn, or Ala residue did not significantly affect the epoxide hydrolase activity of LTA4H (Table II). Values of Vmax (kcat) and Km for [Q136L], [Q136N], and [Q136A]LTA4H reached 20-57% and 18-179% of the wild type control, respectively. On the other hand, the mutations led to highly variable effects on both the turnover, and the Michaelis constant for the peptidase substrate Ala-p-NA (Table II). Thus, [Q136L]LTA4H did not obey saturation kinetics and displayed a linear increase in reaction velocity in the substrate interval 0.125-8.0 mM Ala-p-NA. In contrast, [Q136N]LTA4H lacked almost completely the ability to hydrolyze Ala-p-NA, whereas the peptidase activity of [Q136A]LTA4H did not differ from that of wild type enzyme, with values of Vmax (kcat) and Km mounting to 103 and 108%, respectively. This large variation in the effects of mutation of Gln-136 makes it difficult to draw any conclusions regarding its functional role. However, since the mutant in which the side chain was extensively truncated retained all of its peptide-cleaving ability, the most likely interpretation is that Gln-136 does not play any significant role in this catalytic reaction.
Structure of [E271Q]LTA4H-- The mutant and wild type enzymes crystallize non-isomorphously and also bind a different number of Yb3+ ions. Thus, the wild type enzyme crystallizes in space-group P21212 with three Yb3+ ligands per asymmetric unit, whereas the mutant enzyme crystallizes in space-group P212121 with only one Yb3+ ligand per asymmetric unit.
In the wild type structure, the Zn2+ ion is coordinated to His-295, His-299, one carboxylic oxygen of Glu-318, and the hydroxyl and carbonyl oxygens of bestatin in a pentavalent coordination sphere, forming a square-based pyramid (Fig. 2). In the structure of [E271Q]LTA4H, the Zn2+ is bound to its three canonical amino acid ligands and one carboxylic oxygen of an acetate molecule. These four ligands form an almost ideal tetrahedral coordination geometry. The acetate molecule is also hydrogen-bonded to Tyr-383 and Gln-271.
Exchange of Glu-271 for a Gln does not cause any significant
conformational change of the active site (Fig.
3). Superpositioning of the mutant and
wild type models gives an overall r.m.s. deviation for 610
-carbons
of 0.45 Å. Inspection of the superimposed models shows that the
differences are evenly spread over the molecules. The only exceptions
are two surface loops, which exhibit higher r.m.s. deviations; these
differences in
-carbon positioning are probably due to crystal
packing differences. Of note, residues lining the active site,
including the deeper part of the hydrophobic pocket, show a positional
shift in relation to the wild type structure, which is comparable with
the rest of the molecule. Thus, the major outline of the active site is
well conserved in the mutant structure. However, when comparing the
structures of the wild type and mutated enzyme in detail, a small
rearrangement of spatially neighboring residues can be observed, which
may be explained by the mutation and/or the absence of inhibitor in the
crystal of [E271Q]LTA4H. Directly affected residues, besides Glu-271,
are Glu-296 and Gln-136. The changes are subtle and mainly affect the
hydrogen-bonding network.
|
The orientation of the amide side-chain of Gln-271 cannot be judged from electron density, and it was instead determined based on changes in hydrogen-bonding network. Glu-271 in the wild type structure is hydrogen-bonded to its own backbone amide and to the free amine of the bound inhibitor bestatin. In [E271Q]LTA4H, the orientation of the amide side group does not allow direct interaction with its backbone amide. Instead, new direct hydrogen bonds are observed to the acetate bound in the active site and to a water molecule now occupying the position held by the free amine of bestatin in the wild type structure. The absence of inhibitor and the hydrogen bonding to the amide group of Gln-271 pull Glu-296 toward the backbone amide of Gln-271.
Furthermore, in the mutant structure, Gln-136 is flipped about 90 degrees, which creates a hydrogen bond to Glu-271 and to a new water molecule replacing the free amine of bestatin. Another water molecule, at a position corresponding to the phenyl ring of bestatin, also makes a hydrogen bond to Gln-136. Thus, both the mutation and the absence of inhibitor could explain the positional change of Gln-136. Similarly, the torsional flip observed for Met-270 and the positional shift of Gln-134 are most likely effects caused by the absence of inhibitor.
Modeling of Ala-p-NA into the Active Site of
LTA4H--
Ala-p-NA is a good aminopeptidase substrate for
LTA4H. The binding conformation with the lowest energy of a docked
Ala-p-NA at the active site of LTA4H agreed very well with
biochemical data and is presented in Fig.
4. Thus, the free amine of
Ala-p-NA donates one hydrogen bond to each of the carboxyl
groups of Glu-271 and Glu-318 and one to the amine carbonyl oxygen of
Gln-136. Furthermore, the amide carbonyl oxygen of Ala-p-NA
is bound to the Zn2+ ion, and the carbonyl carbon is at a
suitable position for attack from a water molecule activated by
Glu-296. In addition, Tyr-383, which is believed to act as a proton
donor in the final step of the peptidase reaction, is appropriately
hydrogen-bonded to the amide nitrogen of the substrate. This alignment
of Ala-p-NA indicates that it is a chemically good mimetic
of tripeptides, the preferred aminopeptidase substrates of LTA4H
(15). Moreover, this conclusion agrees well with the fact that the
amino- and nitro-groups of Ala-p-NA are separated by the
same number of covalent bonds as the N and C termini in tripeptide
substrates.
|
| |
DISCUSSION |
|---|
|
|
|---|
Recently, we solved the x-ray crystal structure of LTA4H in complex with bestatin at 1.95 Å resolution (22). At the zinc site, in juxtaposition to the previously identified catalytic residues, Glu-296 and Tyr-383, a Glu and Gln residue were located in seemingly strategic positions, and their interactions with the inhibitor bestatin indicated that they could well be involved in the aminopeptidase reaction (Fig. 2). The carboxylic acid, Glu-271, is conserved among members of the M1 family of metallopeptidases in a GXMEN motif (Fig. 1), whereas the amine, Gln-136, is not well conserved within this enzyme family. To detail the functional role of Glu-271 and Gln-136 for the two catalytic activities of LTA4H, they were subjected to mutational analysis.
Glu-271 Is a Common Catalytic Residue in Both the Epoxide Hydrolase and Peptidase Reactions-- Exchange of Glu-271 for a Gln, Ala, or Leu residue completely abolished the ability of LTA4H to convert LTA4 into LTB4 (Table II) as well as its amide cleaving activity against Ala-p-NA (Table II). In contrast, mutation of any of the remaining residues within the GXMEN motif preserved a significant epoxide hydrolase and peptidase activity. On the other hand, mutagenetic replacements of Gln-136 did not allow us to ascribe any specific functional role for this residue (Table II).
The finding that mutation of Glu-271 abolishes both catalytic activities of LTA4H was unexpected and warranted further studies to rule out that the recombinant proteins had lost the prosthetic zinc or had undergone major conformational changes at the active site. To this end, we determined the x-ray crystal structure of the mutant with the most conservative replacement, i.e. [E271Q]LTA4H. This structure revealed the presence of the catalytic metal and an almost completely conserved overall architecture, particularly at the active site, which demonstrates that the loss of enzyme function was site-specific and could be attributed to the removal of the carboxylate from the side chain of residue 271. Hence, we conclude that Glu-271 is involved in key steps of the epoxide hydrolase and peptidase reactions. In fact, Glu-271 is the first amino acid, besides the three zinc-binding ligands, that has been shown to be required for the epoxide hydrolase mechanism. Moreover, to our knowledge, this is the first example of a single amino acid residue that is critical and common for two distinct catalytic reactions, which turn over lipid and peptide substrates, respectively.
Role of Glu-271 in the Epoxide Hydrolase Mechanism, Assistance in
an Acid-induced Activation, and Opening of the Epoxide--
Based on
the structure of LTA4H as well as data obtained by studies of
structure activity relationships of tight-binding hydroxamic acid
inhibitors, we recently proposed a mechanistic model for enzymatic
hydrolysis of LTA4 into LTB4 (22, 32). It
postulates that LTA4 is bound to the active site with the
oxirane ring near the zinc ion and the C7-C20 olefinic tail buried in a
narrow, L-shaped, hydrophobic pocket in the protein. In
this model, which apparently is incomplete, the zinc acts as a weak
Lewis acid to activate and open the epoxide ring. In light of the
present mutational data and the fact that Glu-271 is located in the
immediate vicinity of the zinc, it seems likely that Glu-271 is
required in the initial epoxide activation. Thus, we propose that
Glu-271 polarizes a water molecule bound to the zinc and that the
resulting proton will catalyze an acid-induced opening of the oxirane
ring (Fig. 5A). This
SN1 reaction will generate a carbocation
intermediate whose positive charge will be delocalized over the
conjugated triene system. In the last step of the reaction, a
nucleophilic attack will occur at C12 to introduce the
12R-hydroxyl group of LTB4 (Fig.
5A).
|
Even if several lines of evidence support this model, we cannot rule out an alternative mechanism, which includes the formation of an ester intermediate. In this scheme, the zinc alone activates and opens the epoxide, and the carboxylate of Glu-271 attacks LTA4 at C6 to form an ester intermediate. In a concerted SN2' reaction, this ester can then be attacked by an hydroxyl group or a carboxylate at C12, and the negative charge can move along the conjugated triene system, eventually leading to an alkyl-oxygen cleavage instead of a normal ester cleavage (Fig. 5B). This model is attractive since formation of an alkylenzyme ester intermediate is a key feature in the mechanisms of other epoxide hydrolases, in particular soluble and microsomal epoxide hydrolase (33-36). In this context it is interesting to note that LTA4 is an excellent substrate of soluble epoxide hydrolase, which converts the allylic 5S,6R-epoxide into a 5S,6R dihydroxy acid (37). On the other hand, the crystal structure of soluble epoxide hydrolase was recently solved and revealed no structural similarity with LTA4H (35). In addition, alkyl-oxygen cleavages of esters are rare reactions although they have been described for certain allylic or benzylic esters (38).
Role of Glu-271 in the Aminopeptidase Reaction, an N-terminal Recognition Site for Peptide Substrates, and a Determinant for the Exopeptidase Specificity of LTA4H-- The total loss of aminopeptidase activity in [E271Q]LTA4H points to a critical role of Glu-271 in this catalytic mechanism. Several lines of evidence indicate that this residue acts as an anionic binding site for peptide substrates. Thus, in the structure of LTA4H in complex with bestatin, Glu-271 makes hydrogen bonds to the free amine of the inhibitor, which chemically resembles a peptide substrate (22). Furthermore, Glu-271 is ideally positioned in the structure to bind the N terminus of Ala-p-NA or an arginyl tripeptide, the preferred peptidase substrate of LTA4H. In addition, this residue, or any equivalent functionality, is absent in the structure of thermolysin, a classical zinc endopeptidase that accommodates peptide substrates of any length (39). In agreement with the crystallographic data, modeling of Ala-p-NA, a chemically good mimetic of a tripeptide substrate into the active site of LTA4H, positions Glu-271 within hydrogen bonding distance to the terminal amino group of the substrate (Fig. 4). Together, these data imply that Glu-271 acts as an N-terminal recognition site for peptide substrates, and in this capacity Glu-271 will play a critical role for the exopeptidase nature of the peptide-cleaving activity of LTA4H. The drastic effects of mutations on kcat with abolishment of catalytic activity suggest that Glu-271 may also be involved in the stabilization of the transition-state (Table II). For APN and APA, it has been suggested that such a transition-state involves an interaction between the nitrogen of the N-terminal amino group of the peptide substrate and the catalytic zinc (18, 19). However, in our model for the binding of Ala-p-NA, the distance between these two atoms is too long to allow such an interaction (Fig. 4). Instead, the model indicates that the amino group of the substrate is positioned within hydrogen-bonding distance to Glu-318.
The model for binding of Ala-p-NA is in excellent agreement
with previous biochemical and mutational data and implies that Glu-271,
as well as Glu-296 and Tyr-383, can be fitted into a general base
mechanism for the aminopeptidase activity (Fig.
6). Thus, in the energy-minimized binding
conformation, the carbonyl oxygen of Ala-p-NA is indeed
bound to the Zn2+, and Glu-296 is ideally positioned to
polarize a water molecule for nucleophilic attack at the carbonyl
carbon (Fig. 4). Furthermore, in this model Tyr-383 is located close
enough to the peptide nitrogen to function as a proton donor.
|
Sequence alignments have previously been used to identify the conserved
GXMEN motif within the M1 family of zinc peptidases without
knowing its functional relevance (12). Further studies with
site-directed mutagenesis on APN, APA, and oxytocinase, have suggested
that the equivalent of Glu-271 is involved in the aminopeptidase reaction, presumably as an anionic binding site for the
-amino group
of peptidic substrates (18, 19, 40). However, these studies have been
limited by the fact that the mutated enzymes were not purified before
kinetic characterization and by the lack of a crystal structure for any
member of the enzyme family to be used as a template for mechanistic
models. Nevertheless, when comparing these earlier data with the
results of the present investigation, they are certainly in good
agreement. Considering the fact that our conclusions regarding the
functional role of Glu-271 are based on a combination of mutational
analysis and x-ray crystallography, we believe that they can be
generalized to include all members of the M1 family of
metallopeptidases. Hence, we think it is now justified to denote the
GXMEN sequence a consensus motif for an N-terminal
recognition site in zinc aminopeptidases.
| |
ACKNOWLEDGEMENTS |
|---|
We thank personnel at Beamline I711 of MAX-Lab, Lund, Sweden for help during data collection, Martina Andberg for discussions and advice, and Eva Ohlson for excellent technical assistance.
| |
FOOTNOTES |
|---|
* The Swedish Medical Research Council (O3X-10350), the Swedish Foundation for Strategic Research, the Swedish Natural Sciences Research Council, The European Union (QLG1-CT-2001-01521), and Konung Gustav V:s 80-Årsfond funded this work.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed. Tel.: 46-8-728-76-12; Fax: 46-8-736-04-39; E-mail: jesper.haeggstrom@mbb.ki.se.
Published, JBC Papers in Press, October 23, 2001, DOI 10.1074/jbc.M106577200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: LT, leukotriene(s); LTA4, leukotriene A4, 5S-trans-5,6-oxido-7,9-trans-11,14-cis-eicosatetraenoic acid; LTB4, leukotriene B4, 5S,12R-dihydroxy-6,14-cis-8,10-trans-eicosatetraenoic acid; LTA4H, LTA4 hydrolase; APA, aminopeptidase A; APB, aminopeptidase B; APN, aminopeptidase N; HPLC, high performance liquid chromatography; 5S, 6R-DHETE, 5S,6R-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid; 5S, 6S-DHETE, 5S,6S-dihydroxy-7,9-trans-11,14-cis-eicostetraenoic acid; PGB1, prostaglandin B1; bestatin, [(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine; Ala-p-NA, alanine para-nitroanilide; Leu-p-NA, leucine para-nitroanilide; Lys-p-NA, lysine para-nitroanilide.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Samuelsson, B. (1983) Science 220, 568-575 |
| 2. | Samuelsson, B., Dahlén, S.-E., Lindgren, J.-Å., Rouzer, C. A., and Serhan, C. N. (1987) Science 237, 1171-1176 |
| 3. | Ford-Hutchinson, A. W., Bray, M. A., Doig, M. V., Shipley, M. E., and Smith, M. J. H. (1980) Nature 286, 264-265 |
| 4. | Griffiths, R. J., Smith, M. A., Roach, M. L., Stock, J. L., Stam, E. J., Milici, A. J., Scampoli, D. N., Eskra, J. D., Byrum, R. S., Koller, B. H., and McNeish, J. D. (1997) J. Exp. Med. 185, 1123-1129 |
| 5. | Bailie, M. B., Standiford, T. J., Laichalk, L. L., Coffey, M. J., Strieter, R., and Peters-Golden, M. (1996) J. Immunol. 157, 5221-5224 |
| 6. | Mancuso, P., Nana-Sinkam, P., and Peters-Golden, M. (2001) Infect. Immun. 69, 2011-2016 |
| 7. | Chen, X. S., Sheller, J. R., Johnson, E. N., and Funk, C. D. (1994) Nature 372, 179-182 |
| 8. | Byrum, R. S., Goulet, J. L., Snouwaert, J. N., Griffiths, R. J., and Koller, B. H. (1999) J. Immunol. 163, 6810-6819 |
| 9. | Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., and Shimizu, T. (1997) Nature 387, 620-624 |
| 10. | Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., and Shimizu, T. (2000) J. Exp. Med. 192, 421-431 |
| 11. | Haeggström, J. Z. (2000) Am. J. Resp. Crit. Care Med. 161, S25-S31 |
| 12. | Barret, A. J., Rawlings, N. D., and Woessner, J. F. (1998) in Handbook of Proteolytic Enzymes (Barret, A. J. , Rawlings, N. D. , and Woessner, J. F., eds) , pp. 994-996, Academic Press, London |
| 13. | Vallee, B. L., and Auld, D. S. (1990) Biochemistry 29, 5647-5659 |
| 14. | Medina, J. F., Wetterholm, A., Rådmark, O., Shapiro, R., Haeggström, J. Z., Vallee, B. L., and Samuelsson, B. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7620-7624 |
| 15. | Orning, L., Gierse, J. K., and Fitzpatrick, F. A. (1994) J. Biol. Chem. 269, 11269-11273 |
| 16. | Wetterholm, A., Medina, J. F., Rådmark, O., Shapiro, R., Haeggström, J. Z., Vallee, B. L., and Samuelsson, B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9141-9145 |
| 17. | Blomster, M., Wetterholm, A., Mueller, M. J., and Haeggström, J. Z. (1995) Eur. J. Biochem. 231, 528-534 |
| 18. | Vazeux, G., Iturrioz, X., Corvol, P., and Llorenz-Cortez, C. (1998) Biochem. J. 334, 407-413 |
| 19. | Luciani, N., Marie-Claire, C., Ruffet, E., Beaumont, A., Roques, B. P., and Fournié-Zaluski, M.-C. (1998) Biochemistry 37, 686-692 |
| 20. | Mueller, M. J., Wetterholm, A., Blomster, M., Jörnvall, H., Samuelsson, B., and Haeggström, J. Z. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8383-8387 |
| 21. | Mueller, M. J., Blomster, M., Oppermann, U. C. T., Jornvall, H., Samuelsson, B., and Haeggström, J. Z. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5931-5935 |
| 22. | Thunnissen, M. G. M., Nordlund, P., and Haeggström, J. Z. (2001) Nat. Struct. Biol. 8, 131-135 |
| 23. | Sarkar, G., and Sommer, S. S. (1990) BioTechniques 8, 404-407 |
| 24. | Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 |
| 25. | Wetterholm, A., Haeggström, J. Z., Samuelsson, B., Yuan, W., Munoz, B., and Wong, C. H. (1995) J. Pharmacol. Exp. Ther. 275, 31-37 |
| 26. | Otwinowski, Z. (1993) Data Collection and Processing. Proceedings of the CCP 4 Study Weekend , pp. 56-62, SERC Daresbury Laboratory, Warrington, UK |
| 27. | Navaza, J. (1994) Acta Crystallogr. Sect. A 50, 157-163 |
| 28. | Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 905-921 |
| 29. | McRee, D. E. (1999) J. Struct. Biol. 125, 156-165 |
| 30. | Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., and Olson, A. J. (1998) J. Comput. Chem. 19, 1639-1662 |
| 31. | Stewart, J. J. P. (1990) J. Comput. Aided Mol. Des. 4, 1-45 |
| 32. | Hogg, J. H., Ollmann, I. R., Wetterholm, A., Blomster Andberg, M., Haeggström, J. Z., Samuelsson, B., and Wong, C.-H. (1998) Chem. Eur. J. 4, 1697-1713 |
| 33. | Arand, M., Grant, D. F., Beetham, J. K., Friedberg, T., Oesch, F., and Hammock, B. D. (1994) FEBS Lett. 338, 251-256 |
| 34. | Arand, M., Wagner, H., and Oesch, F. (1996) J. Biol. Chem. 271, 4223-4229 |
| 35. | Argiriadi, M. A., Morisseau, C., Hammock, B. D., and Christianson, D. W. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 10637-10642 |
| 36. | Zou, J., Hallberg, B. M., Bergfors, T., Oesch, F., Arand, M., Mowbray, S. L., and Jones, T. A. (2000) Structure 8, 111-122 |
| 37. | Haeggström, J. Z., Meijer, J., and Rådmark, O. (1986) J. Biol. Chem. 261, 6332-6337 |
| 38. | March, J. (1985) Advanced Organic Chemistry , John Wiley & Sons, New York |
| 39. | Holmes, M. A., and Matthews, B. W. (1982) J. Mol. Biol. 160, 623-639 |
| 40. | Laustsen, P. G., Vang, S., and Kristensen, T. (2001) Eur. J. Biochem. 268, 98-104 |
| 41. | Guex, N., and Peitsch, M. C. (1997) Electrophoresis 18, 2714-2723 |
This article has been cited by other articles:
![]() |
C. Bauvois, L. Jacquamet, A. L. Huston, F. Borel, G. Feller, and J.-L. Ferrer Crystal Structure of the Cold-active Aminopeptidase from Colwellia psychrerythraea, a Close Structural Homologue of the Human Bifunctional Leukotriene A4 Hydrolase J. Biol. Chem., August 22, 2008; 283(34): 23315 - 23325. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ito, Y. Nakajima, Y. Onohara, M. Takeo, K. Nakashima, F. Matsubara, T. Ito, and T. Yoshimoto Crystal Structure of Aminopeptidase N (Proteobacteria Alanyl Aminopeptidase) from Escherichia coli and Conformational Change of Methionine 260 Involved in Substrate Recognition J. Biol. Chem., November 3, 2006; 281(44): 33664 - 33676. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chavez-Gutierrez, E. Matta-Camacho, J. Osuna, E. Horjales, P. Joseph-Bravo, B. Maigret, and J.-L. Charli Homology Modeling and Site-directed Mutagenesis of Pyroglutamyl Peptidase II: INSIGHTS INTO OMEGA-VERSUS AMINOPEPTIDASE SPECIFICITY IN THE M1 FAMILY J. Biol. Chem., July 7, 2006; 281(27): 18581 - 18590. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Tholander, F. Kull, E. Ohlson, J. Shafqat, M. M. G. M. Thunnissen, and J. Z. Haeggstrom Leukotriene A4 Hydrolase, Insights into the Molecular Evolution by Homology Modeling and Mutational Analysis of Enzyme from Saccharomyces cerevisiae J. Biol. Chem., September 30, 2005; 280(39): 33477 - 33486. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Diaz-Perales, V. Quesada, L. M. Sanchez, A. P. Ugalde, M. F. Suarez, A. Fueyo, and C. Lopez-Otin Identification of Human Aminopeptidase O, a Novel Metalloprotease with Structural Similarity to Aminopeptidase B and Leukotriene A4 Hydrolase J. Biol. Chem., April 8, 2005; 280(14): 14310 - 14317. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Oldham, A. R. Brash, and M. E. Newcomer The structure of coral allene oxide synthase reveals a catalase adapted for metabolism of a fatty acid hydroperoxide PNAS, January 11, 2005; 102(2): 297 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Z. Haeggstrom Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis J. Biol. Chem., December 3, 2004; 279(49): 50639 - 50642. [Full Text] [PDF] |
||||
![]() |
P. C. Rudberg, F. Tholander, M. Andberg, M. M. G. M. Thunnissen, and J. Z. Haeggstrom Leukotriene A4 Hydrolase: IDENTIFICATION OF A COMMON CARBOXYLATE RECOGNITION SITE FOR THE EPOXIDE HYDROLASE AND AMINOPEPTIDASE SUBSTRATES J. Biol. Chem., June 25, 2004; 279(26): 27376 - 27382. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hong, K. Gronert, P. R. Devchand, R.-L. Moussignac, and C. N. Serhan Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells. AUTACOIDS IN ANTI-INFLAMMATION J. Biol. Chem., April 18, 2003; 278(17): 14677 - 14687. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chandu, A. Kumar, and D. Nandi PepN, the Major Suc-LLVY-AMC-hydrolyzing Enzyme in Escherichia coli, Displays Functional Similarity with Downstream Processing Enzymes in Archaea and Eukarya. IMPLICATIONS IN CYTOSOLIC PROTEIN DEGRADATION J. Biol. Chem., February 14, 2003; 278(8): 5548 - 5556. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rozenfeld, X. Iturrioz, B. Maigret, and C. Llorens-Cortes Contribution of Molecular Modeling and Site-directed Mutagenesis to the Identification of Two Structural Residues, Arg-220 and Asp-227, in Aminopeptidase A J. Biol. Chem., August 2, 2002; 277(32): 29242 - 29252. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Rudberg, F. Tholander, M. M. G. M. Thunnissen, B. Samuelsson, and J. Z. Haeggstrom Leukotriene A4 hydrolase: Selective abrogation of leukotriene B4 formation by mutation of aspartic acid 375 PNAS, April 2, 2002; 99(7): 4215 - 4220. [Abstract] [Full Text] [PDF] |
||||
|
|